Business Segment Information

9 Months Ended

Sep. 30, 2020

15. Business Segment Information

The Company has three reportable segments, BSI Life Science, BSI NANO and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements.

Revenue and operating income by reportable segment are presented below (dollars in millions):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Revenue:
BSI Life Science	$	323.4	$	301.9	$	842.6	$	869.3
BSI NANO		147.1		169.9		392.7		461.7
BEST		43.8		52.5		134.8		152.2
Eliminations (a)		(2.9)		(3.2)		(10.1)		(10.5)
Total revenue	$	511.4	$	521.1	$	1,360.0	$	1,472.7

Operating Income (loss)
BSI Life Science	$	80.6	$	75.7	$	158.7	$	178.9
BSI NANO		12.2		18.3		9.3		27.1
BEST		1.2		3.6		5.1		9.9
Corporate, eliminations and other (b)		(12.8)		(9.8)		(37.6)		(32.7)
Total operating income	$	81.2	$	87.8	$	135.5	$	183.2

(a)	Represents product and service revenue between reportable segments.

(b)	Represents corporate costs and eliminations not allocated to the reportable segments.

Total assets by reportable segment are as follows (dollars in millions):


	September 30,		December 31,
	2020		2019
Assets:
BSI Life Science, BSI NANO & Corporate	$	2,808.9	$	2,711.6
BEST		76.5		64.6
Eliminations and other (a)		(6.0)		(4.7)
Total assets	$	2,879.4	$	2,771.5

(a)	Assets not allocated to the reportable segments and eliminations of intercompany transactions.

The Company is unable, without unreasonable effort or expense to disclose the amount of total assets by BSI Life Science and BSI NANO Segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.